NANOBIOTIX TO PRESENT POSITIVE
RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF
NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS)
AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND
ASTRO ANNUAL CONFERENCES
- Dr. Sylvie Bonvalot will present positive results from
its Phase II/III clinical trial of NBTXR3 in soft tissue sarcoma
(STS):
- Oral communication in the Sarcoma Proffered Paper
presentation session at the European Society for Medical Oncology
(ESMO) 2018 Congress
- Oral communication in the late-breaking abstract
session at the American Society for Radiation Oncology (ASTRO) 60th
Annual Meeting
- 7 additional posters on NBTXR3 clinical trials (liver
cancers, head and neck cancers and immuno-oncology) will be
presented during the ESMO 2018 Congress and the ASTRO 60th Annual
Meeting
Paris, France and Cambridge,
Massachusetts, September 26, 2018 – NANOBIOTIX (Euronext:
NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine
company pioneering new approaches in the treatment of cancer,
announced today that detailed results of its phase II/III clinical
trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be
presented by Dr. Sylvie Bonvalot, MD, PhD at the ESMO 2018 Congress
in Munich (Germany) on the 19th of October 2018 during the
Proffered Paper (Oral) presentation - Sarcoma and at the ASTRO 60th
Annual Meeting in San Antonio (USA) on the 21st of October 2018
during the late-breaking abstract session.
European Society for Medical Oncology
(ESMO) 2018 CongressOctober 19 – 23, 2018 –
Munich, Germany
- A phase II/III trial of hafnium oxide nanoparticles
activated by radiotherapy in the treatment of locally advance soft
tissue sarcoma of the extremity and trunk wall
(LBA66)
Oral communication presented by Dr. Sylvie
Bonvalot, MD, PhD (Paris, France) during the Proffered Paper
presentation - SarcomaDate: 10.19.2018
- Elderly patients with locally advanced head and neck
squamous cell carcinoma treated with NBTXR3 nanoparticles activated
by radiotherapy: a phase I trial (1058P)
Poster presented by Prof. Christophe Le Tourneau
(Paris, France)Date: 10.21.2018
- Hepatocellular carcinoma and liver metastasis treated
by hafnium oxide nanoparticles activated by stereotactic body
radiation therapy (711P)
Poster presented by Dr. Marc Pracht (Rennes,
France) Date: 10.21.2018
American Society for Radiation Oncology (ASTRO) 60th
Annual Meeting
October 21 – 24, 2018 – San Antonio,
Texas, United States
- Act.in.Sarc: An International Randomized Phase III
Trial Evaluating Efficacy and Safety of First-in-Class NBTXR3
Hafnium Oxide Nanoparticles Activated by Preoperative Radiotherapy
in Locally Advanced Soft Tissue Sarcoma (LBA7)
Oral communication presented by Dr. Sylvie
Bonvalot, MD, PhD (Paris, France) during the late-breaking abstract
sessionDate: 10.23.2018
- Hafnium Oxide Nanoparticles Activated by Radiation
Therapy for the Treatment of Solid Tumors
(SU_44_2434)
Poster presented by Prof. Juliette Thariat, MD,
PhD (Caen, France)Date: 10.21.2018
- Hafnium Oxide Nanoparticles Activated by Radiation
Therapy: An Innovative Approach for the Treatment of Liver Cancers
(SU_13_2124)
Poster presented by Dr. Enrique Chajon
Rodriguez, MD, PhD (Rennes, France)Date: 10.21.2018
- Elderly patients: NBTXR3 as a novel treatment option in
locally advanced HNSCC (MO_10_2547)
Poster presented by Dr. Valentin Calugaru, MD
(Paris, France)Date: 10.22.2018
- Exploratory Dosimetric Study of the Impact of the
Pre-Radiation Therapy Intra Tumoral Injection of Hafnium Oxide
Nanoparticles Along the Radiation Treatment of Extremity and Trunk
Wall Soft Tissue Sarcomas (MO_15_2596)
Poster presented by Eliane Graulieres, PhD
(Toulouse, France)Date: 10.22.2018
- Hafnium Oxide Nanoparticle Activated by Radiation
Therapy Generates an Anti-Tumor Immune Response
(1096)
Poster presented by Prof. Juliette Thariat, MD,
PhD (Caen, France)Date: 10.23 2018
***
About NBTXR3NBTXR3 is a
first-in-class product designed to destroy, when activated by
radiotherapy:
- tumors through physical cell death
- metastasis due to immunogenic cell death leading to activation
of the immune system
NBTXR3 has a high degree of biocompatibility,
requires one single administration before the whole radiotherapy
treatment and Nanobiotix believes has the ability to fit into
current worldwide standards of radiation care.
Nanobiotix’s broad clinical program includes 10
patient population evaluated in 7 clinical trials.In June 2018,
Nanobiotix established human proof of concept for this
first-in-class product in its Soft Tissue Sarcoma (STS) Phase III
clinical trial.
NBTXR3 is actively being evaluated in head and
neck cancer with locally advanced squamous cell carcinoma of the
oral cavity or oropharynx in elderly and frail patients that are
unable to receive chemotherapy or cetuximab and have very limited
therapeutic options. Promising results have been observed from the
ongoing Phase I/II trial regarding the local control of the
tumors.
Nanobiotix is running an Immuno-Oncology
development program. In the United States, Nanobiotix has received
approval from the U.S. Food and Drug Administration (FDA) to launch
a clinical study of NBTXR3 activated by radiotherapy in combination
with anti-PD1 antibodies in lung, and head and neck cancer patients
(head and neck squamous cell carcinoma and non-small cell lung
cancer).
The other ongoing NBTXR3 trials are treating
patients with liver cancers (hepatocellular carcinoma and liver
metastasis), locally advanced or unresectable rectal cancer in
combination with chemotherapy, head and neck cancer in combination
with concurrent chemotherapy, and prostate adenocarcinoma.
The first market authorization process (CE
Marking) is ongoing in Europe in the STS indication.
About
NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage
nanomedicine company pioneering new approaches to significantly
change patient outcomes by bringing nanophysics to the heart of the
cell.
The Nanobiotix philosophy is one rooted in
designing pioneer physical based approaches to bring highly
effective and generalized solutions to address high unmet medical
needs and challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NanoXray, aims to expand radiotherapy benefits for
millions of cancer patients. Furthermore, Nanobiotix’s
Immuno-Oncology program has the potential to bring a new dimension
to cancer immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are based in Paris, France,
with a U.S. affiliate in Cambridge, MA, and European affiliates in
Spain and Germany.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director,
Investor Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Ricky Bhajun Investor
Relations Europe +33 (0)1 79 97 29 99 ricky.bhajun@nanobiotix.com /
investors@nanobiotix.com |
Media relations |
|
France -
Springbok ConsultantsMarina
Rosoff+33 (0)6 71 58 00 34marina@springbok.fr |
|
United States –
RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
|
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business
prospects, including statements regarding the clinical development
of its product candidates, including NBTXR3, and timing and
developments regarding its Phase II/III clinical trial of NBTXR3 in
patients with soft tissue sarcoma. Such forward-looking statements
are based on assumptions that Nanobiotix considers to be
reasonable. However, there can be no assurance that the estimates
contained in such forward-looking statements will be verified,
which estimates are subject to numerous risks including the risks
set forth in the reference document of Nanobiotix filed with the
French Financial Markets Authority (Autorité des Marchés
Financiers) under number D.17-0470 on April 28, 2017 as well as in
its 2017 annual financial report filed with the French Financial
Markets Authority on March 29, 2018 (copies of which are available
on www.nanobiotix.com) and to the development of economic
conditions, financial markets and the markets in which Nanobiotix
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Nanobiotix or
not currently considered material by Nanobiotix. The occurrence of
all or part of such risks could cause actual results, financial
conditions, performance or achievements of Nanobiotix to be
materially different from such forward-looking statements.
At the moment, NBTXR3 does not bear a CE mark
and is not permitted to be placed on the market or put into service
until NBTXR3 has obtained a CE mark. Forward-looking statements
speak only as of the date of this release, and Nanobiotix
undertakes no obligation to update or revise these statements,
except as may be required by law.
- PR_Nanobiotix_ESMO-ASTRO_20180926_VF
Nanobiotix (EU:NANO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024